Routine assessment and management of neonatal pain has evolved to become an
important therapeutic goal in the twenty-first century. During the twentieth century, however …

Background Indomethacin is used as standard therapy to close a patent ductus arteriosus
(PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo …

Background Indomethacin is the conventional treatment for patent ductus arteriosus in
preterm infants. However, its use is associated with various side effects. In a prospective …

Background Patent ductus arteriosus (PDA) complicates the clinical course of preterm
infants and increases the risk of adverse outcomes. Indomethacin has been the standard …

Background Indomethacin is used as standard therapy to close a patent ductus arteriosus
(PDA) but is associated with reduced blood flow to several organs. Ibuprofen, another cyclo …

Importance Interventions to reduce severe brain injury risk are the prime focus in neonatal
clinical trials. Objective To evaluate multiple perinatal interventions across clinical settings …

Recent advances in neurobiology and clinical medicine have established that the fetus and
newborn may experience acute, established, and chronic pain. They respond to such …

Objective: To evaluate the effect of intravenous ibuprofen and indomethacin for treatment of
patent ductus arteriosus (PDA) on mesenteric and renal blood flow velocity in preterm …

Indomethacin (INDO) and, more recently, ibuprofen (IBU) have been used to treat
haemodynamically significant patent ductus arteriosus (PDA) in preterm infants. Both are …

Patent ductus arteriosus (PDA) is a common problem in very preterm infants. It results in a
significant left-to-right shunt and an increase in left ventricular output. Pulmonary compliance …